| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Nilotinib-d3 is the deuterated form of nilotinib, which is an orally available Bcr-Abl tyrosine kinase inhibitor. Nilotinib targets the Bcr-Abl fusion protein, a constitutively active tyrosine kinase that drives the proliferation of leukemic cells in chronic myeloid leukemia (CML). The deuterated version is used as a tracer for quantitation.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The in vitro activity of Nilotinib-d3 mirrors that of nilotinib, which is a potent Bcr-Abl tyrosine kinase inhibitor. Nilotinib-d3 is used as an internal standard to accurately quantify nilotinib in cell-based experiments. |
| ln Vivo |
In vivo, Nilotinib-d3 is used as a tracer to study the pharmacokinetics and metabolism of nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity used in the treatment of CML.
|
| Enzyme Assay |
The primary application of Nilotinib-d3 is as an internal standard in LC-MS/MS assays. A known amount of the labeled compound is added to biological samples (e.g., plasma). Following protein precipitation and extraction, the sample is analyzed by LC-MS/MS. The internal standard corrects for variability in the analytical process.
|
| Cell Assay |
In cellular assays, Nilotinib-d3 is used to quantify the intracellular concentration of nilotinib. This allows researchers to study drug uptake and accumulation in leukemic cell lines.
|
| Animal Protocol |
In animal studies, Nilotinib-d3 is utilized as an internal standard for the quantification of nilotinib in pharmacokinetic studies. Following administration to animal models, blood samples are collected at various time points and analyzed by LC-MS/MS.
|
| ADME/Pharmacokinetics |
Nilotinib-d3 is a chemically stable compound with a molecular weight of 532.53. Deuteration involves replacing hydrogen atoms with deuterium, which can alter the pharmacokinetic properties of the compound without significantly affecting its pharmacological activity.
|
| Toxicity/Toxicokinetics |
Nilotinib-d3 is intended for research use only and is not for therapeutic or diagnostic use in humans. As a stable isotope, it is non-radioactive and poses minimal radiological risk. Its toxicological profile is expected to be similar to that of nilotinib, which may cause myelosuppression and hepatotoxicity.
|
| References |
|
| Additional Infomation |
Nilotinib-d3 is a high-purity stable isotope-labeled compound used as an internal standard for the bioanalysis of nilotinib. It is also known as AMN 107-d3 and Tasigna-d3. It is an essential tool in drug development for studying the pharmacokinetics of this important tyrosine kinase inhibitor.
|
| Molecular Formula |
C28H19D3F3N7O
|
|---|---|
| Molecular Weight |
532.53
|
| Exact Mass |
532.203
|
| CAS # |
1215678-43-5
|
| Related CAS # |
Nilotinib;641571-10-0
|
| PubChem CID |
49849405
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.812
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
39
|
| Complexity |
817
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
|
| InChi Key |
HHZIURLSWUIHRB-BMSJAHLVSA-N
|
| InChi Code |
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)/i2D3
|
| Chemical Name |
4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-N-[3-[4-(trideuteriomethyl)imidazol-1-yl]-5-(trifluoromethyl)phenyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8778 mL | 9.3891 mL | 18.7783 mL | |
| 5 mM | 0.3756 mL | 1.8778 mL | 3.7557 mL | |
| 10 mM | 0.1878 mL | 0.9389 mL | 1.8778 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
